Goldman Sachs Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $12

Benzinga · 01/14 14:10
Goldman Sachs analyst Salveen Richter maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and lowers the price target from $19 to $12.